Feed / ELV

Elevance Health, Inc.

ELV

Healthcare · 417.98 +5.2% today

Isolated · not yet confirmedMarket checked 11 Sept, 10:55 GMT-4

Market read

Elevance Health, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 7 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.

Company+5.2% todayVolume comparison unavailable
Market group0 of 7 activeHealthcare Plans · unavailable
Disclosed network0 of 3 confirmingNo filing-linked name is confirming now
What would change this read
  • CarelonRx delegates certain core pharmacy services to CaremarkPCS (CVS) under an agreement with a contractual term through December 31, 2027.

Invalidation: The isolated read changes if ELV's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Healthcare Plans

No new filing conclusion is available. 0 of 7 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • CarelonRx delegates certain core pharmacy services to CaremarkPCS (CVS) under an agreement with a contractual term through December 31, 2027.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations601
Usable filing statements197
Verified relationships3
Evidence supporting the case
  • Latest annual revenue changed +12.5% year over year.
Evidence challenging the case
  • Credit and interest rates has repeated adverse evidence across 5 filings.
Questions before a position
  • P/E is 53% below the available filing-peer median; determine whether growth and quality justify the difference.
  • EV/sales is 32% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 10, 2026

416.44
6m+43.7%12m+32.2%24m-23.5%
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$138.6B+13.8%$24.95-2.9%
2022-12-31$156.6B+13.0%$24.28-1.6%
2023-12-31$171.3B+9.4%$25.22-2.2%
2024-12-31$177.0B+3.3%$25.68-1.9%
2025-12-31$199.1B+12.5%$25.21-3.6%

What management says matters

Persistent and emerging business drivers

Credit and interest ratesmixed · 5 filings
Other expense decreased primarily due to a decrease in amortization of other intangible assets due to assets being amortized under an accelerated depreciation method, which results in higher expense recognition in earlier periods and progressively lower amort…
10-Q · Jul 15, 2026
Restructuring and cost reductionsnegative · 3 filings
Net losses on financial instruments decreased due to lower impairment on other invested assets and lower realized losses on sales of financial instruments.
10-Q · Jul 15, 2026
Legal and regulatory exposurenegative · 2 filings
Operating loss decreased primarily due to the non-recurring accrual recorded during the year ended December 31, 2024 for the Provider Settlement Agreement associated with the BCBSA Litigation and lower business optimization charges in the year ended December…
10-K · Feb 6, 2026
Industry cycle and competitionmixed · 1 filings
We intend to utilize this authorization over a multi-year period, subject to market and industry conditions.
10-K · Feb 6, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales 0.5× · EV/sales 0.6×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

417.98+5.2% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 10:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for ELV. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for ELV. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind ELV

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

CVSCVS Health CorporationpartnerFeb 6, 2026

CarelonRx delegates certain core pharmacy services to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation (“CVS”), pursuant to an agreement (the “CVS Agreement”) with the current contractual term extending through December 31, 2027.

UNHUnitedHealth Group IncorporatedinvesteeFeb 6, 2026

Boudreaux was Executive Vice President of UnitedHealth Group Incorporated (“UHGI”) (diversified healthcare company) from 2008 to 2015.

Depended on by

CLOVClover Health Investments, Corp.competitorFeb 27, 2026

Our competitors generally include large, national insurers, such as United Health, Aetna, Humana, Centene, and Elevance Health that provide MA plans, as well as regional-based companies or health plans that provide MA plans, including Blue Cross Blue Shield a…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

ELV is currently a Follower in the organic co-movement group Healthcare Plans. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.